Chest discomfort

Chest discomfort is a common but heterogeneous symptom that can arise from cardiac ischemia, non‑cardiac thoracic structures, gastrointestinal reflux, pulmonary embolism, pneumothorax, mediastinal masses, or psychogenic factors such as anxiety. Differentiating benign from life‑threatening causes requires rapid assessment of ECG findings, serial troponin measurements, and careful evaluation of risk factors including high blood pressure, diabetes and tobacco use. While cardiac etiologies often present with exertional pressure or squeezing pain that may radiate to the left arm or neck, non‑cardiac sources such as GERD, PE, spontaneous pneumothorax and esophageal disorders typically produce pleuritic, burning or positional discomfort. Psychological contributors, notably anxiety and panic attacks, can generate chest sensations through autonomic hyperactivation and hyperventilation, further complicating the diagnostic picture. Contemporary emergency protocols emphasize an integrated algorithm that combines immediate ECG, high‑sensitivity troponin testing, validated decision tools (e.g., TIMI, HEART) and targeted imaging such as CTPA or CCTA to stratify risk and guide timely intervention, while avoiding unnecessary invasive procedures in low‑risk patients. Early recognition of atypical presentations—particularly in women, the elderly and diabetic individuals—along with appropriate safety‑netting and patient education, improves outcomes and reduces both over‑ and under‑triage.

Physiological mechanisms and classification of chest discomfort

Chest discomfort can be divided into cardiac and non‑cardiac categories, each arising from distinct physiological pathways. Understanding these mechanisms is essential for accurate classification and subsequent management.

Cardiac mechanisms

Myocardial ischemia—an imbalance between oxygen supply and demand—activates nociceptors within the heart. The afferent pain signal travels via spinal cardiac afferent fibers to the thalamus and cerebral cortex, utilizing neurotransmitters such as substance P, glutamate, and TRPV1 receptors^[1]. Vagal afferents may also convey atypical or referred pain through the nucleus of the solitary tract and spinal segments C1‑C2, explaining chest discomfort without classic pressure sensations^[1]. Psychological factors, particularly activity of the amygdala, can modulate the perception of cardiac pain, and convergent input from other viscera (e.g., gastrointestinal tract) may produce referred pain to the chest^[1].

Non‑cardiac mechanisms

Non‑cardiac chest discomfort originates from thoracic structures other than the myocardium and typically involves one or more of the following processes:

Source	Primary Mechanism	Typical Pain Quality
Gastroesophageal reflux disease (GERD), esophageal spasm	Acid irritation or abnormal muscular contraction of the esophagus	Burning, substernal, often related to meals or lying down
Musculoskeletal (muscle strain, rib fracture, costochondritis)	Mechanical injury or inflammation of chest‑wall structures	Localized, reproducible with palpation or movement
Respiratory (pleuritis, pneumonia, pulmonary embolism)	Irritation or inflammation of the pleura or pulmonary parenchyma	Sharp, pleuritic pain that worsens with deep inspiration
Neurological / Psychiatric (anxiety, panic attacks)	Autonomic hyperactivation → sympathetic surge, hyperventilation, muscle tension	Tightness or pressure‑like sensation, often together with dyspnea, sweating, or dizziness

Unlike the exertional, pressure‑type pain of cardiac ischemia, non‑cardiac discomfort frequently has identifiable triggers (e.g., certain foods, posture, movement) and lacks a clear supply‑demand mismatch^[4]^[5].

Classification schema

Based on the underlying physiology, chest discomfort is commonly classified into three broad groups:

Ischemic cardiac pain – due to supply‑demand imbalance, often exertional, may radiate to shoulder, arm, neck, jaw.
Non‑ischemic thoracic pain – includes gastrointestinal, musculoskeletal, and pulmonary sources as described above.
Psychogenic or neuro‑visceral pain – mediated by central nervous system pathways (amygdala, vagal afferents) and autonomic dysregulation; frequently associated with anxiety or panic disorders.

This classification guides the selection of diagnostic tests (e.g., ECG and troponin for suspected ischemia, endoscopy or pH‑impedance monitoring for GERD, CT pulmonary angiography for embolism) and informs risk‑stratification tools such as the TIMI score or HEART pathway.

Clinical features that distinguish benign from life‑threatening causes

Identifying which episodes of chest discomfort are likely benign and which herald a life‑threatening event is a core skill in emergency and primary‑care practice. The distinction rests on a combination of pain quality, triggering and relieving factors, associated systemic symptoms, and objective findings such as an ECG or troponin result. The following overview integrates the key clinical patterns described in the source data and highlights the most reliable bedside clues.

Pain quality and reproducibility

Feature	Typical of benign sources	Typical of life‑threatening sources
Intensity & consistency	Mild‑to‑moderate, often localized and reproducible with palpation, movement, or changes in body position.	Severe, pressure‑ or squeezing‑like discomfort that is persistent and not relieved by rest or simple measures.
Radiation	Rarely radiates beyond the chest wall.	Frequently spreads to the **[[Shoulder
Relation to exertion	Frequently exertion‑independent; may improve with rest or antacids.	Often exertional or occurs at rest in unstable presentations (e.g., acute coronary syndrome).
Response to nitroglycerin	May improve, but relief is non‑specific; can occur in esophageal spasm.	Classic relief is a clue but absence of relief does not exclude cardiac ischemia.

Associated symptoms

Symptom	Benign patterns	Life‑threatening patterns
Dyspnea	Mild, related to musculoskeletal strain or reflux.	Marked shortness of breath, often with tachypnea (common in [[Pulmonary embolism
Nausea / vomiting	Occasional, especially with gastrointestinal triggers.	Prominent nausea, vomiting, or diaphoresis suggesting myocardial ischemia.
CNS signs	Usually absent.	Dizziness, syncope, or altered mental status (possible in massive PE or aortic dissection).
Fever / chills	May accompany infectious pleuritis but not typical of cardiac ischemia.	Fever can be present with PE or mediastinal infection, but its absence does not rule out acute coronary events.

Physical examination clues

Chest wall tenderness or reproducible pain on palpation strongly favors a musculoskeletal or costochondral source.
Absence of ECG changes (no ST‑segment deviation, T‑wave inversion, or pathological Q‑waves) supports a benign etiology, whereas new ischemic changes strongly point toward acute coronary syndrome.
Elevated troponin with a dynamic rise/fall pattern confirms myocardial injury. Stable chronic elevations without a change are less specific.
Signs of hemodynamic compromise (hypotension, tachycardia, distended neck veins) raise immediate concern for tension spontaneous pneumothorax or massive PE.

Risk‑factor weighting

Patients with established high blood pressure, diabetes, tobacco use, dyslipidemia, or a strong family history of coronary disease are more likely to experience a life‑threatening coronary event. Conversely, younger individuals without these risk factors and with a clear musculoskeletal or gastrointestinal trigger are more likely to have a benign cause.

Decision tools and imaging

Validated risk‑stratification scores such as the TIMI and HEART incorporate history, ECG, and troponin data to categorize patients into low, intermediate, or high risk. In low‑risk patients, early discharge with safety‑netting is appropriate. High‑risk patients proceed to urgent imaging—**CTPA** for suspected PE or CCTA for coronary assessment—to confirm the diagnosis and guide definitive therapy.

Summary of distinguishing cues

Benign chest discomfort: mild, localized, reproducible, minimal or no radiation, absent ECG/biomarker abnormalities, and a clear non‑cardiac trigger.
Life‑threatening chest discomfort: pressure‑type pain, radiation to arm/neck, occurring at rest or with minimal exertion, accompanied by autonomic (diaphoresis, nausea) or hemodynamic instability, with ECG ischemia and/or troponin rise.

Prompt recognition of these patterns enables clinicians to prioritize rapid investigation for acute coronary syndrome, PE, or tension pneumothorax while avoiding unnecessary invasive testing in truly low‑risk patients.

Emergency diagnostic algorithm: ECG, biomarkers and risk‑stratification tools

Rapid assessment of acute chest discomfort in the emergency setting depends on a structured algorithm that combines immediate electrocardiography, serial cardiac biomarker measurement, and validated risk‑stratification tools. This approach enables clinicians to differentiate life‑threatening cardiac syndromes from benign causes, prioritize urgent interventions, and avoid unnecessary testing.

Initial ECG acquisition

The cornerstone of the algorithm is a 12‑lead electrocardiogram (ECG) performed within 10 minutes of patient arrival. Early ECG identifies classic ischemic patterns—ST‑segment elevation, new left bundle‑branch block, or pathologic Q waves—that mandate prompt reperfusion therapy for ST‑segment elevation myocardial infarction (STEMI) <AHA>. Even when the ECG is nondiagnostic, the presence of subtle changes such as T‑wave inversions or ST‑segment depression can flag unstable angina or non‑ST‑elevation myocardial infarction (NSTEMI) and guide further testing <ECG>.

Serial high‑sensitivity cardiac biomarkers

Following ECG, high‑sensitivity troponin I or T is measured at presentation and repeated 3–6 hours later. Serial sampling detects dynamic rises or falls that confirm myocardial injury, distinguishing NSTEMI from unstable angina or non‑cardiac pain. Elevated troponin levels also refine risk classification and influence decisions about invasive coronary angiography <troponin>.

Clinical risk‑stratification tools

Integrating ECG and biomarker data with clinical variables (age, hypertension, diabetes, smoking, family history) yields quantitative risk scores. Widely used tools include:

TIMI score – predicts 30‑day major adverse cardiac events in patients with suspected acute coronary syndrome (ACS) <TIMI score>.
HEART pathway – incorporates History, ECG, Age, Risk factors, and Troponin to identify low‑risk patients suitable for early discharge <HEART score>.
GRACE score – estimates in‑hospital mortality for ACS and guides intensity of care <GRACE>.

Patients are categorized as low, intermediate, or high risk, which directly determines subsequent investigations and therapeutic urgency.

Decision pathways by risk category

Risk level	Typical findings	Recommended next step
Low	Normal ECG, negative or minimally elevated troponin, low TIMI/HEART score	Observation, possible discharge with safety‑netting instructions; consider outpatient stress testing if uncertainty persists
Intermediate	Nondiagnostic ECG, modest troponin rise, moderate risk score	Coronary computed tomography angiography (CCTA) or stress imaging to rule out obstructive disease; early cardiology consultation
High	ST‑elevation or new LBBB, significant troponin rise, high risk score	Immediate activation of catheterization laboratory for primary percutaneous coronary intervention (PCI) or surgical embolectomy for high‑risk pulmonary embolism; consider adjunctive imaging (CTPA) if alternative diagnoses are suspected

Role of targeted imaging

When ECG and biomarkers are inconclusive, imaging refines the differential:

CCTA is preferred for intermediate‑risk patients to visualize coronary anatomy quickly and accurately, often replacing stress testing <CCTA>.
CT pulmonary angiography (CTPA) or ventilation–perfusion scanning is employed when clinical features (pleuritic pain, tachycardia, hypoxia) suggest pulmonary embolism, especially after a negative ECG for ischemia <PE>.
Chest radiography and bedside ultrasound aid in recognizing tension pneumothorax or large pleural effusions that can mimic cardiac pain.

Safety‑netting and follow‑up

Even low‑risk patients receive explicit safety‑netting instructions: warning signs (persistent chest pain, dyspnea, diaphoresis), when to return to the emergency department, and a scheduled outpatient follow‑up within 48‑72 hours. Documentation of the risk‑stratification score and repeat biomarker results supports continuity of care and reduces missed diagnoses.

Summary

The emergency diagnostic algorithm for chest discomfort follows a reproducible sequence:

Immediate 12‑lead ECG (<10 min) to detect overt ischemia.
Serial high‑sensitivity troponin to identify myocardial injury.
Application of risk scores (TIMI, HEART, GRACE) to classify patients.
Targeted imaging (CCTA, CTPA) for intermediate‑risk or atypical presentations.
Risk‑appropriate management—discharge, non‑invasive testing, or urgent invasive therapy.
Structured safety‑netting to ensure early detection of evolving pathology.

By integrating these elements, clinicians achieve rapid, accurate triage, prioritize life‑saving interventions for high‑risk individuals, and minimize unnecessary testing in low‑risk patients, ultimately improving outcomes and resource utilization.

Imaging modalities for cardiac, pulmonary and mediastinal evaluation

Accurate delineation of the anatomic source of chest discomfort relies on targeted imaging that can differentiate cardiac ischemia, pulmonary embolism, pneumothorax, pleuritis, and mediastinal masses. Contemporary emergency protocols integrate rapid, high‑resolution modalities to both confirm life‑threatening pathology and guide definitive therapy.

Cardiac imaging

Coronary computed tomography angiography (CCTA) is now a first‑line non‑invasive test for patients with intermediate pre‑test probability of coronary artery disease. By visualizing coronary lumen and wall, CCTA can rule out obstructive lesions when high‑sensitivity troponin results are equivocal, thereby avoiding unnecessary invasive coronary angiography ^[6]. In the acute setting, a 12‑lead ECG performed within 10 minutes remains the cornerstone for detecting ST‑segment changes; when CCTA is positive for high‑grade stenosis, early reperfusion strategies are instituted.

Cardiac magnetic resonance imaging (CMR) provides tissue characterization that distinguishes acute myocardial edema, infarction, and microvascular obstruction. High‑resolution T1/T2 mapping quantifies edema, while late gadolinium enhancement identifies necrotic myocardium, supporting diagnosis of myocardial infarction when angiography is ambiguous ^[7]. CMR is especially valuable in patients with atypical presentations—older adults, women, or diabetics—where classic chest pain may be absent.

Pulmonary imaging

CT pulmonary angiography (CTPA) is the definitive imaging tool for suspected pulmonary embolism (PE). It directly visualizes intraluminal filling defects in the pulmonary arteries and can simultaneously assess right‑ventricular strain, a marker of hemodynamic compromise. Rapid CTPA acquisition, guided by validated risk scores such as the Wells criteria, enables timely reperfusion therapy for high‑risk PE ^[8].

Chest radiography remains essential for the initial evaluation of pneumothorax and pleuritis. A plain X‑ray can reveal a visceral‑pleural line and absent lung markings in tension pneumothorax, prompting emergent needle decompression. For pleuritis, radiographs may show pleural effusion or localized infiltrate; bedside ultrasound can further delineate fluid collections and guide thoracentesis.

Ventilation‑perfusion (V/Q) scanning serves as an alternative to CTPA when contrast administration is contraindicated (e.g., severe renal insufficiency). A mismatched perfusion defect with normal ventilation strongly suggests PE, though specificity is lower than CTPA.

Mediastinal imaging

Contrast‑enhanced chest CT is the workhorse for evaluating mediastinal masses. It defines the compartment (anterior, middle, posterior), size, calcification, and relationship to adjacent vessels and airways. When a mass is identified, CT guides subsequent image‑guided transthoracic needle biopsy or endoscopic ultrasound‑guided fine‑needle aspiration, providing tissue diagnosis while minimizing invasiveness ^[9].

Magnetic resonance imaging (MRI) offers superior soft‑tissue contrast for complex mediastinal lesions, particularly when vascular invasion or spinal extension is suspected. MRI can differentiate cystic from solid components, aiding surgical planning for video‑assisted thoracoscopic surgery (VATS) or robotic resections.

Transesophageal echocardiography (TEE) is reserved for suspected aortic dissection, a critical differential when chest discomfort is described as tearing or ripping. TEE rapidly identifies an intimal flap and true‑ versus false‑lumen anatomy, facilitating emergent surgical repair ^[10].

Integration into the diagnostic algorithm

Immediate ECG and bedside ultrasound to rule out acute coronary syndrome and identify pneumothorax.
Risk stratification (e.g., HEART, TIMI, Wells) determines whether the next step is CCTA, CTPA, or direct CT chest.
Select imaging modality based on clinical probability and contraindications:
- CCTA for intermediate‑risk coronary disease.
- CTPA for suspected PE.
- Contrast CT or MRI for mediastinal masses or aortic pathology.
Definitive tissue diagnosis (CT‑guided biopsy, endobronchial ultrasound) when imaging reveals a mass but does not establish etiology.
Therapeutic planning (e.g., VATS resection of a mediastinal tumor, catheter‑directed embolectomy for PE, surgical embolectomy for massive PE, or emergent thoracostomy for tension pneumothorax) is guided by the precise anatomic information provided by the chosen imaging study.

By employing a tiered, evidence‑based imaging strategy, clinicians can rapidly distinguish life‑threatening cardiac, pulmonary, and mediastinal causes of chest discomfort, prioritize urgent interventions, and avoid unnecessary invasive procedures in low‑risk patients.

Esophageal and gastrointestinal sources of chest discomfort

Chest discomfort that originates from the esophagus or other gastrointestinal structures is a common non‑cardiac cause of the symptom and often mimics cardiac pain. The most frequent disorders are GERD, esophageal spasm, and structural lesions such as a hiatal hernia. These conditions produce characteristic patterns of pain, associated symptoms, and responses to therapy that help separate them from cardiac or pulmonary disease.

Typical symptom pattern

Burning or substernal pressure that frequently worsens after meals, when lying flat, or with intake of fatty, spicy, or caffeinated foods – a classic presentation of acid reflux‑related discomfort.
Radiation to the throat, neck, or back is common, whereas true myocardial ischemia more often spreads to the left arm, jaw, or shoulder.
Temporal relationship to meals or body position is a strong clue; symptoms may improve after antacid administration, unlike cardiac pain that is usually relieved by rest or nitroglycerin.
Associated gastro‑intestinal signs such as regurgitation, sour taste, dysphagia, or chronic cough further point toward an esophageal source.

Initial evaluation

Because life‑threatening cardiac disease must be excluded first, the initial work‑up mirrors that for any chest discomfort: a rapid 12‑lead ECG and measurement of troponin are performed to rule out acute coronary syndrome. When these tests are normal and the clinical picture suggests an esophageal cause, targeted gastrointestinal assessment can be pursued.

Diagnostic algorithm for esophageal chest discomfort

Empiric trial of acid suppression – a short course of a proton‑pump inhibitor (PPI) may be prescribed; symptom relief supports GERD but does not confirm the diagnosis.
Upper endoscopy (EGD) – indicated when alarm features (e.g., dysphagia, weight loss, bleeding) are present or when persistent symptoms warrant mucosal evaluation for erosive esophagitis, strictures, or Barrett’s esophagus.
Ambulatory pH‑impedance monitoring – the gold‑standard for quantifying both acid and non‑acid reflux episodes and for correlating reflux events with reported chest discomfort. This test is especially valuable when symptoms persist despite PPI therapy.
High‑resolution manometry – performed when motility disorders are suspected (e.g., diffuse esophageal spasm, achalasia) or before anti‑reflux surgery to confirm normal peristalsis and rule out functional abnormalities.

The stepwise approach minimizes invasive procedures while ensuring that clinically significant pathology is not missed.

Role of pH‑impedance testing

Ambulatory pH‑impedance testing detects reflux episodes that are invisible to standard pH studies, including weakly acidic or non‑acid events. It also provides a temporal link between reflux and the patient’s reported chest discomfort, thereby establishing a causal relationship. Evidence shows that this correlation improves diagnostic accuracy and guides personalized therapy, particularly in patients with refractory symptoms.

Endoscopic assessment

Endoscopy offers direct visualization of the esophageal mucosa. It can identify:

Erosive esophagitis – indicating acid injury.
Hiatal hernia – a mechanical factor that promotes reflux.
Structural lesions such as strictures, rings, or neoplasia that may produce chest pain independent of reflux.

When mucosal injury is confirmed, the severity of esophagitis can be staged, informing the intensity and duration of acid‑suppression therapy.

Manometric evaluation

Esophageal manometry measures intraluminal pressure patterns along the esophagus. It is essential for diagnosing:

Achalasia – characterized by absent peristalsis and elevated lower esophageal sphincter pressure.
Esophageal spasm – marked by premature, high‑amplitude contractions that produce chest‑like pain.

Manometry results also dictate suitability for surgical or endoscopic anti‑reflux procedures, as abnormal motility may contraindicate certain techniques.

Integrating findings into management

The combination of symptom assessment, endoscopic visualization, pH‑impedance correlation, and manometric data enables a precise diagnosis. Management pathways include:

Lifestyle modification – weight reduction, head‑of‑bed elevation, avoidance of trigger foods, and cessation of tobacco.
Pharmacologic therapy – optimized PPI dosing, H2‑receptor antagonists, or pro‑kinetic agents for motility disorders.
Endoscopic interventions – radiofrequency ablation for refractory GERD, dilation for strictures, or per‑oral endoscopic myotomy (POEM) for achalasia.
Surgical options – laparoscopic fundoplication for well‑documented reflux with proven anatomical defect, or thoracoscopic myotomy for spasm unresponsive to medical therapy.

Key take‑aways

Esophageal sources of chest discomfort are usually burning, position‑related, and meal‑associated and often improve with acid suppression.
Exclusion of cardiac disease with ECG and troponin testing is the first step; once ruled out, a structured gastrointestinal work‑up—starting with empiric therapy and progressing through endoscopy, pH‑impedance, and manometry—provides definitive diagnosis.
Accurate identification of the underlying esophageal mechanism guides targeted, often minimally invasive, therapy, improves symptom control, and prevents unnecessary cardiac investigations.

Psychogenic and somatoform chest pain: assessment and management

Psychogenic or somatoform chest pain refers to chest discomfort that originates primarily from psychological processes rather than detectable structural disease. Patients often describe the pain as pressure, tightness, or a vague aching sensation that may be triggered by stress, anxiety, or panic episodes. Although the symptom can be severe enough to prompt emergency evaluation, objective cardiac, pulmonary, gastrointestinal, or musculoskeletal investigations are usually normal. Recognizing this entity early prevents unnecessary invasive testing and hospital admission while allowing targeted therapeutic interventions.

Clinical features suggesting a psychogenic origin

Feature	Typical presentation in psychogenic chest pain
Pain quality	Burning, stabbing, or tightness that is not reproducible with palpation or movement.
Triggers	Emotional stress, panic attacks, anxiety spikes; often occurs at rest.
Associated symptoms	Hyperventilation, heart palpitations, sweating, dizziness; may improve with relaxation techniques.
Response to nitroglycerin	Often absent or minimal relief, unlike true cardiac ischemia.
ECG/biomarkers	Normal 12‑lead ECG (performed within 10 minutes of presentation) and serial high‑sensitivity troponin values remain within reference range.
Risk factor profile	Lack of traditional cardiovascular risk factors (e.g., hypertension, diabetes, smoking).

These patterns differ from ACS where pain is usually exertional, radiates to the left arm or jaw, and is accompanied by ECG changes or troponin elevation, and from GERD where symptoms are often post‑prandial and improve with antacids.

Assessment strategy

Comprehensive history and physical examination – Emphasize the temporal relationship between symptoms and psychological stressors; assess for panic‑type features such as sudden onset dyspnea and fear of dying.
Rule out life‑threatening organic causes – Obtain a prompt ECG and, if indicated, serial cardiac biomarkers; consider bedside ultrasound to exclude pneumothorax or effusion when respiratory findings are present.
Psychiatric screening – Use validated tools (e.g., GAD‑7, PHQ‑9) to identify underlying anxiety, panic disorder, or depressive illness.
Risk stratification – Apply clinical decision pathways such as the HEART score to confirm low cardiac risk before focusing on psychogenic management.

Management principles

1. Patient education and safety‑netting

Explain that the chest discomfort is real but not caused by heart disease; provide clear instructions on red‑flag symptoms (e.g., new exertional pain, syncope, persistent dyspnea) that require immediate reevaluation.
Provide written discharge instructions summarizing the evaluation, reassurance of normal test results, and guidance on when to seek care.

2. Multidisciplinary collaboration

Involve primary care teams, psychiatrists, and psychologists early to ensure coordinated care.
When patients present to the emergency department, a consult with a mental‑health specialist can streamline referral to outpatient psychotherapy, reducing repeat visits.

3. Cognitive‑behavioral therapy (CBT)

CBT targets catastrophic misinterpretation of benign sensations, teaches controlled breathing, and reduces avoidance behaviors. Randomized trials show sustained reductions in chest‑pain frequency and healthcare utilization after internet‑delivered CBT programs.
Core CBT components include cognitive restructuring of health‑related fears, exposure to feared bodily sensations, and relaxation training.

4. Pharmacologic options (when indicated)

For patients meeting criteria for GAD or panic attacks, first‑line agents such as selective serotonin reuptake inhibitors (SSRIs) or serotonin‑norepinephrine reuptake inhibitors (SNRIs) can lower overall anxiety levels and thereby decrease chest discomfort episodes.
Short‑acting benzodiazepines may be used judiciously for acute panic episodes but should be limited to avoid dependence.

5. Lifestyle modification

Encourage regular aerobic exercise, weight management, and avoidance of excessive caffeine or nicotine, all of which can lower baseline anxiety and improve cardiovascular fitness.
Mindfulness‑based stress reduction and progressive muscle relaxation are useful adjuncts that have demonstrated efficacy in reducing somatic symptom burden.

Follow‑up and outcome monitoring

Schedule an early follow‑up (within 1–2 weeks) with the primary care provider or mental‑health clinician to assess response to CBT or medication.
Re‑measure anxiety scales (e.g., GAD‑7) and document changes in chest‑pain frequency.
Adjust therapeutic intensity based on symptom trajectory; persistent pain despite optimal CBT may warrant reassessment for occult organic disease.

Evidence‑based benefits

Systematic reviews report that CBT reduces the number of painful days by up to 30 % and lowers unnecessary emergency department visits.
Multidisciplinary pathways that integrate mental‑health evaluation reduce hospital admission rates for non‑cardiac chest pain by approximately 20 % and improve patient satisfaction scores.

Key takeaways

Distinguish psychogenic chest pain by its non‑exertional onset, lack of ECG or biomarker abnormalities, and strong correlation with anxiety or panic states.
Apply a structured assessment that first excludes cardiac, pulmonary, gastrointestinal, and musculoskeletal causes.
Provide clear reassurance, safety‑netting instructions, and prompt referral to CBT‑based psychotherapy, with adjunctive pharmacotherapy for comorbid anxiety disorders.
Engage a multidisciplinary team to ensure comprehensive care, minimize repeat presentations, and improve long‑term functional outcomes.

Specific pulmonary and mediastinal emergencies (PE, pneumothorax, mediastinal masses)

Pulmonary and mediastinal emergencies are among the most life‑threatening causes of chest discomfort and demand rapid recognition, targeted imaging, and decisive intervention. The three most common entities—pulmonary embolism (PE), spontaneous or tension pneumothorax, and mediastinal tumors or cysts—share a presentation of sudden, pleuritic chest pain but differ markedly in associated findings, diagnostic pathways, and urgent management priorities.

Pulmonary embolism

PE typically presents with sudden‑onset pleuritic chest pain that worsens with deep inspiration and is frequently accompanied by acute dyspnea, tachycardia, and, in up to one‑third of patients, hemoptysis ^[11]. Physical examination may reveal signs of right‑heart strain, and bedside electrocardiography can show sinus tachycardia, S1Q3T3 pattern, or right‑bundle‑branch‑block‑like changes ^[12].

Risk stratification tools such as the Wells score or PERC criteria guide the decision to obtain a D‑dimer assay; a normal result effectively rules out PE in low‑risk patients, whereas an elevated D‑dimer mandates definitive imaging. CT pulmonary angiography (CTPA) is the gold‑standard diagnostic modality, directly visualizing intraluminal filling defects in the pulmonary arteries. When CTPA is contraindicated, a ventilation–perfusion (V/Q) scan provides an alternative functional assessment.

Management hinges on the patient’s hemodynamic status. High‑risk PE (hypotension, shock, or right‑heart failure) requires urgent reperfusion—either systemic thrombolysis, catheter‑directed thrombolysis, or surgical pulmonary embolectomy in cases where thrombolysis is contraindicated or ineffective ^[13]. Intermediate‑risk patients are treated with anticoagulation and close monitoring, while low‑risk individuals may be discharged on oral anticoagulants after a brief observation period, provided they receive clear safety‑netting instructions.

Pneumothorax

A pneumothorax produces unilateral, sharp, pleuritic chest pain plus acute dyspnea. Physical findings are characteristic: decreased or absent breath sounds, hyperresonance to percussion, and reduced chest expansion on the affected side. Tension pneumothorax, the most critical variant, adds tracheal deviation away from the lesion, distended neck veins, hypotension, and signs of obstructive shock ^[14].

Prompt bedside chest radiography confirms the diagnosis by revealing a visible pleural line and lung collapse. When the clinical picture is unmistakable, treatment should not be delayed for imaging. Immediate needle decompression in the second intercostal space, mid‑clavicular line, relieves intrathoracic pressure, followed by definitive chest tube thoracostomy. For uncomplicated primary pneumothorax, video‑assisted thoracoscopic surgery (VATS) pleurodesis reduces recurrence rates, while larger or traumatic pneumothoraces often require open thoracotomy.

Mediastinal masses

Mediastinal masses generate dull, aching chest discomfort that may be persistent rather than pleuritic, frequently accompanied by constitutional symptoms such as weight loss, fever, or night sweats when malignant or infectious. The mass’s location (anterior, middle, or posterior compartment) influences both symptomatology and therapeutic approach.

Cross‑sectional imaging—contrast‑enhanced CT or MRI—is essential for delineating the mass’s size, relationship to vascular and airway structures, and for planning biopsies. Image‑guided transthoracic needle biopsy (fine‑needle aspiration or core biopsy) yields a histopathologic diagnosis while minimizing invasiveness ^[9]. When the lesion is resectable, video‑assisted thoracoscopic surgery (VATS) or robot‑assisted thoracic surgery provides definitive removal with reduced postoperative pain and shorter hospital stay compared with open thoracotomy ^[16].

Urgent surgical intervention is required for masses causing airway compression, superior vena cava syndrome, or pericardial involvement; in these scenarios, rapid airway protection and vascular management are priorities while awaiting pathological confirmation.

Integrated early‑recognition algorithm

Rapid bedside assessment – obtain a 12‑lead ECG and vital signs within 10 minutes of presentation.
Identify red‑flags – hypotension, hypoxia, tracheal deviation, or signs of right‑heart strain → treat as tension pneumothorax or high‑risk PE immediately.
Apply risk‑stratification tools – Wells score/PERC for PE, clinical criteria for tension pneumothorax, and symptom‑duration/constitutional signs for mediastinal masses.
Targeted imaging –
- CTPA for suspected PE.
- Portable chest X‑ray (or point‑of‑care ultrasound) for pneumothorax.
- Contrast CT/MRI for mediastinal masses.
Definitive therapy – needle decompression → chest tube (pneumothorax); anticoagulation ± reperfusion (PE); VATS or robotic resection (mediastinal mass).
Safety‑netting and follow‑up – provide clear discharge instructions, arrange early imaging or specialist review, and educate patients on warning signs (worsening dyspnea, recurrent chest pain, hemodynamic instability).

By recognizing the distinct clinical patterns—exertional versus positional pain, unilateral breath‑sound changes, or systemic constitutional features—and by deploying the appropriate imaging modality without delay, clinicians can swiftly differentiate between PE, pneumothorax, and mediastinal masses, initiate life‑saving interventions, and ultimately improve patient survival and quality of care.

Therapeutic interventions: medical, interventional and minimally invasive surgery

Chest discomfort that has been attributed to a cardiac, pulmonary or mediastinal source can be treated with a spectrum of strategies ranging from pharmacologic therapy to image‑guided catheter procedures and minimally invasive thoracic surgery. The choice of intervention is driven by the underlying pathology, the patient’s hemodynamic stability, and the risk‑benefit profile of each modality.

Medical management

Pharmacologic therapy remains the first line for many reversible causes of chest discomfort.

In acute coronary syndrome (ACS), rapid administration of aspirin, P2Y12 inhibitors, and high‑sensitivity troponin‑guided anticoagulation limits thrombus propagation ^[17].
β‑blockers and nitrates relieve ischemic pressure‑type pain by reducing myocardial oxygen demand and improving coronary vasodilation ^[18].
For gastro‑esophageal reflux disease (GERD)‑related discomfort, a trial of proton pump inhibitors (PPIs) at the lowest effective dose is recommended; endoscopic assessment of mucosal healing guides dose titration and prevents long‑term adverse effects ^[19].
Antibiotics are indicated when pleuritic pain is secondary to bacterial pneumonia or empyema.
Systemic thrombolysis is reserved for ST‑segment elevation myocardial infarction (STEMI) when immediate percutaneous reperfusion is unavailable ^[20].
In high‑risk pulmonary embolism (PE) with hemodynamic compromise, systemic thrombolysis or catheter‑directed thrombolysis is employed to rapidly restore pulmonary perfusion ^[21].
Surgical pulmonary embolectomy provides a life‑saving alternative for patients who are contraindicated for thrombolysis or who have failed catheter therapy ^[13].

Interventional cardiology and radiology

When medical therapy alone is insufficient, image‑guided catheter techniques allow rapid reperfusion or definitive diagnosis.

Percutaneous coronary intervention (PCI) with drug‑eluting stent placement restores flow in occluded coronary arteries and is the cornerstone of STEMI management ^[21].
Coronary computed tomography angiography (CCTA) is employed in intermediate‑risk patients to rule out obstructive disease without immediate invasive angiography ^[24].
CT pulmonary angiography (CTPA) is the definitive test for suspected PE, allowing visualization of intraluminal filling defects and guiding the decision for anticoagulation or catheter therapy ^[20].
Catheter‑directed thrombolysis delivers low‑dose fibrinolytic agents directly into the pulmonary artery, reducing systemic bleeding risk while achieving rapid clot lysis ^[24].
Endovascular stent grafting is utilized for selected cases of aortic dissection that involve the thoracic aorta, stabilizing the false lumen and preventing rupture ^[27].

Minimally invasive thoracic surgery

Advances in video‑assisted and robot‑assisted platforms have transformed the operative treatment of pulmonary and mediastinal lesions responsible for chest discomfort.

Video‑assisted thoracoscopic surgery (VATS) pleurodesis or mechanical abrasion provides definitive therapy for recurrent spontaneous pneumothorax, rapidly re‑apposing the visceral and parietal pleura and preventing recurrence ^[28].
Robotic‑assisted thoracic resection enables precise removal of mediastinal masses (e.g., thymomas, neurogenic tumors) with reduced postoperative pain and shorter hospital stay compared with open thoracotomy ^[16].
Thoracoscopic lobectomy using a periareolar approach has been described for early‑stage lung cancer presenting with chest discomfort, offering oncologic control while preserving lung function ^[30].
Hybrid VATS/endoscopic techniques are employed for emergency drainage of large pleural effusions or empyemas, allowing bedside placement of large‑bore chest tubes under direct vision and reducing the need for open thoracotomy ^[31].
Robotic mediastinoscopy facilitates biopsy of centrally located mediastinal masses, providing tissue diagnosis with minimal mediastinal disruption and guiding subsequent definitive resection ^[32].

Integration of therapy and outcomes

A coordinated algorithm that begins with rapid electrocardiography and cardiac biomarker assessment, proceeds to risk stratification (e.g., TIMI or HEART scores), and then selects the appropriate medical, interventional, or minimally invasive surgical pathway has been shown to:

Reduce in‑hospital mortality for STEMI and high‑risk PE by >30 % when reperfusion is achieved within guideline‑specified timeframes.
Decrease repeat emergency department visits for recurrent pneumothorax after VATS pleurodesis, with recurrence rates falling below 5 % in contemporary series.
Improve quality‑of‑life scores after robotic mediastinal tumor resection, owing to lower postoperative pain and faster return to normal activities.

In summary, modern therapeutic interventions for chest discomfort are highly stratified: medical therapy stabilizes reversible ischemia and inflammation; interventional catheter procedures provide rapid reperfusion or definitive diagnosis when anatomy is amenable; and minimally invasive thoracic surgery offers curative treatment for structural pulmonary and mediastinal lesions with minimal morbidity. The selection of the appropriate modality hinges on timely diagnostic accuracy, patient‑specific risk factors, and the availability of expertise in contemporary minimally invasive techniques.

Safety‑netting, patient education and multidisciplinary management strategies

Effective management of chest discomfort requires more than rapid diagnosis; it also depends on robust safety‑netting, clear patient education, and coordinated multidisciplinary care. The goal is to minimise both over‑triage (unnecessary investigations and admissions) and under‑triage (missed life‑threatening disease) while empowering patients to recognise warning signs and seek timely help.

Core safety‑netting principles in primary and pre‑hospital settings

Immediate risk stratification – All patients with acute chest discomfort should receive a 12‑lead ECG within 10 minutes of presentation and a point‑of‑care high‑sensitivity troponin assay when available. Early ECG abnormalities (e.g., ST‑segment elevation, new left bundle‑branch block, or significant T‑wave changes) trigger urgent transport and definitive reperfusion therapy, whereas a normal ECG with low‐risk clinical features supports a more conservative pathway ^[21].
Clinical decision rules – Validated tools such as the PERC, Wells, TIMI and HEART enable clinicians to categorise patients into low, intermediate, or high risk for acute coronary syndrome (ACS) or pulmonary embolism (PE). Integration of these rules with serial troponin trends reduces diagnostic uncertainty and guides disposition decisions ^[20].
Structured discharge instructions – For low‑risk patients who are safely discharged, clinicians must provide written and verbal instructions that outline red‑flag symptoms (e.g., new or worsening pain, dyspnoea, diaphoresis, syncope), clear timelines for follow‑up (often within 48–72 h), and contact information for urgent re‑evaluation. Studies show that explicit safety‑netting instructions markedly lower rates of missed adverse events after discharge ^[35].
Prehospital risk communication – Emergency medical services (EMS) crews should convey a concise risk assessment (e.g., “ST‑elevation on field ECG – transporting for immediate cath lab”) to receiving hospitals, allowing early activation of reperfusion pathways and reducing door‑to‑balloon times ^[21].

Patient education strategies

Symptom awareness – Education campaigns highlight that cardiac pain often presents as pressure, squeezing, or tightness and may radiate to the arm, neck, jaw, or back, whereas non‑cardiac causes such as gastro‑oesophageal reflux disease (GERD) or musculoskeletal strain usually produce burning or reproducible pain that varies with meals or movement. Emphasising these differences helps patients differentiate benign from potentially serious presentations ^[37].
Risk‑factor modification – Interactive counseling on smoking cessation, blood pressure control, lipid management, and regular aerobic activity reduces the long‑term incidence of ischemic chest discomfort. Public‑health programs that promote brisk walking, swimming, or cycling have been linked to lower population‑level coronary disease burden ^[38].
Medication literacy – Patients prescribed PPIs for GERD‑related chest pain often misunderstand dosing. Education emphasizing the lowest effective dose, the need for periodic reassessment of mucosal healing, and the risks of prolonged use (e.g., nutrient deficiencies) improves adherence and prevents unnecessary chronic therapy ^[19].
Psychological support – Anxiety and panic disorders can mimic or amplify chest discomfort. Providing information about the autonomic mechanisms of stress‑induced chest pain, and offering referrals for CBT or mindfulness‑based stress reduction, reduces repeat presentations and unnecessary cardiac work‑ups ^[40].

Multidisciplinary collaboration

Integrated care teams – Optimal pathways involve emergency physicians, cardiologists, pulmonologists, thoracic surgeons, primary‑care providers, and mental‑health professionals. Regular multidisciplinary huddles enable rapid consensus on disposition (e.g., admission for PCI, outpatient CCTA, or referral for thoracic surgery) and streamline hand‑offs ^[41].
Shared decision‑making – Using decision aids that incorporate risk scores and imaging findings, clinicians can involve patients in choosing between invasive coronary angiography, coronary CCTA, or conservative medical management. This approach respects patient preferences while maintaining safety standards ^[21].
Specialist referral pathways – When imaging identifies pulmonary embolism, tension pneumothorax, or mediastinal masses, pre‑established protocols direct patients to thoracic surgery or interventional radiology for prompt intervention (e.g., needle decompression, surgical embolectomy, or video‑assisted thoracoscopic surgery). Clearly defined referral triggers minimise delays and improve outcomes ^[43].

Reducing over‑ and under‑triage through protocol design

Challenge	Protocol solution	Expected impact
Over‑triage – excessive imaging and admissions	Apply low‑risk decision rules (PERC, HEART) with documented negative ECG and stable troponin to discharge with safety‑netting	↓ unnecessary radiation, cost, and hospital length of stay
Under‑triage – missed STEMI or high‑risk PE	Mandatory 12‑lead ECG and immediate point‑of‑care troponin; automated alerts for ST‑elevation or rising troponin trends; EMS‑to‑hospital early notification	↑ timely reperfusion, reduced mortality
Diagnostic uncertainty – atypical presentations in women, elderly, diabetics	Incorporate age‑ and sex‑specific symptom checklists; lower threshold for early imaging (CCTA) when ECG is non‑diagnostic yet risk factors present	↑ detection of occult ischemia, equitable care
Communication gaps – unclear follow‑up	Standardised discharge template with colour‑coded red‑flag list and scheduled telephone check‑in within 48 h	↓ missed adverse events, higher patient satisfaction

Measurable outcomes for evaluating safety‑netting and education initiatives

Rate of missed major adverse cardiac events (MACE) within 30 days among patients discharged after low‑risk stratification.
Proportion of chest‑pain presentations receiving an ECG within 10 minutes and a troponin result within the protocol‑defined window.
Number of unnecessary coronary angiograms or stress tests per 1,000 chest‑pain visits – a surrogate for over‑triage.
Patient‑reported confidence in symptom self‑assessment (e.g., via validated questionnaires) after education sessions.
Utilisation of mental‑health services for anxiety‑related chest discomfort, reflecting appropriate referral and reduced repeat ED use.

Continuous audit of these metrics, combined with feedback loops to front‑line staff, sustains high‑quality safety‑netting while preserving resource efficiency.

In summary, safety‑netting for chest discomfort hinges on rapid, evidence‑based risk stratification, precise patient education on symptom patterns and risk‑factor modification, and seamless multidisciplinary collaboration. Well‑designed protocols that embed validated clinical decision tools, clear discharge instructions, and structured referral pathways effectively balance the twin imperatives of avoiding missed life‑threatening disease and preventing unnecessary investigations.

Epidemiology, triage trends and public‑health approaches to chest discomfort

Chest discomfort remains one of the most frequent reasons for presenting to emergency departments and primary‑care clinics worldwide. Over the past decade, epidemiological data have shown a steady rise in the volume of presentations, a shift toward more atypical symptom patterns, and a growing reliance on structured risk‑stratification tools and digital decision‑support systems. These changes have major implications for public‑health planning, resource allocation, and community education.

Rising burden and shifting presentation patterns

National surveillance in the United States documented an average increase of about 255 chest‑pain visits per emergency department each year between 2006 and 2016, underscoring the persistent demand on acute‑care services ^[44].
Similar trends were observed in Denmark, where ambulance transports for chest pain and confirmed acute myocardial infarction grew year‑by‑year from 2012 to 2018, although the proportion of true myocardial infarctions remained relatively stable ^[45].

Concurrently, the clinical phenotype of chest discomfort has evolved. Over the last 35 years, classic exertional pressure‑type pain has become less common, while atypical presentations—such as isolated dyspnoea, fatigue, nausea, or pain localized to the back or neck—have increased, especially among older adults, women, and patients with diabetes ^[46]. This shift hampers rapid recognition of life‑threatening causes and necessitates broader differential diagnoses in triage protocols.

Contemporary risk‑stratification and triage pathways

Modern emergency algorithms emphasize early ECG acquisition (within 10 minutes), serial high‑sensitivity troponin measurements, and validated clinical decision tools to separate low‑risk from high‑risk patients. Key instruments include the HEART pathway, the TIMI risk score, the PERC rule for pulmonary embolism exclusion, and the Wells criteria.

Implementation of these tools has enabled high‑sensitivity identification of low‑risk individuals suitable for safe discharge, thereby reducing unnecessary admissions and costly imaging. At the same time, high‑risk patients—identified by ST‑segment elevation, dynamic troponin rise, or hemodynamic instability—receive expedited reperfusion or advanced imaging (e.g., CT pulmonary angiography for suspected pulmonary embolism) ^[20].

Integration of artificial intelligence and predictive modelling

In the past five years, machine‑learning algorithms have been incorporated into pre‑hospital and emergency‑department triage platforms. Logistic‑regression and deep‑learning models trained on large registries have demonstrated high sensitivity for predicting major adverse cardiac events and have been used to prioritize ambulance dispatch, allocate cath‑lab resources, and flag patients who may benefit from early coronary computed tomography angiography ^[48].

These AI‑driven tools complement traditional scores, offering real‑time risk estimates that can adapt to evolving vital signs and laboratory results, thereby reducing both over‑triage (unnecessary admissions) and under‑triage (missed acute coronary syndromes).

Public‑health initiatives and preventive strategies

Population‑wide approaches differ from individual clinical care by targeting modifiable risk factors and symptom awareness. Major public‑health programs focus on:

Cardiovascular risk reduction – promotion of regular physical activity (e.g., brisk walking, cycling), dietary improvement, smoking cessation, and aggressive management of hypertension and dyslipidaemia. These measures have been linked to decreases in the incidence of angina and myocardial infarction at the community level ^[49].
Symptom education campaigns – tailored messaging for high‑risk groups (women, older adults, diabetics) that highlights atypical presentations (e.g., unexplained fatigue, epigastric discomfort) and the importance of seeking urgent medical evaluation.
Access to rapid diagnostics – expansion of pre‑hospital ECG capabilities and point‑of‑care troponin testing, particularly in rural or underserved regions, to shorten time‑to‑diagnosis and improve equity of care.

Effectiveness of these initiatives is measured through population‑level outcomes such as:

Declines in cardiovascular mortality and disability‑adjusted life years attributable to coronary artery disease.
Reductions in emergency‑department chest‑pain encounter rates after community education interventions.
Improved door‑to‑balloon times for STEMI patients and higher rates of appropriate discharge for low‑risk chest‑pain cases.
Surveillance of risk‑factor control (blood pressure, LDL‑cholesterol, HbA1c) across demographic groups.

Key implications for emergency response planning

Capacity planning must accommodate the growing number of chest‑pain presentations while preserving rapid access to ECG and biomarker testing.
Protocol standardisation that incorporates validated decision rules and AI risk scores can streamline patient flow, minimise unnecessary testing, and ensure that high‑risk patients receive timely reperfusion or advanced imaging.
Community outreach should emphasise atypical symptom recognition and promote early activation of emergency services, especially in populations traditionally under‑recognised for cardiac disease.
Data integration across pre‑hospital, emergency, and primary‑care information systems enables real‑time monitoring of trends, supports predictive modelling, and guides allocation of resources where the burden is greatest.

By aligning epidemiological surveillance, evidence‑based triage pathways, and preventive public‑health policies, health systems can better balance the dual challenges of over‑triage (excessive admissions and testing) and under‑triage (missed acute events), ultimately improving outcomes for the millions of individuals who experience chest discomfort each year.